Cholecystokinin
CCK, CCK-8, sincalide (synthetic sulfated octapeptide), pancreozymin (historical), CCK-33, CCK-58
Cholecystokinin is a family of gut peptides released from I-cells of the duodenum and jejunum in response to fat and protein. It contracts the gallbladder, triggers pancreatic enzyme secretion, slows gastric emptying and produces the sensation of fullness at the end of a meal. Its synthetic sulfated octapeptide form, sincalide, is a licensed diagnostic agent; as an appetite therapy, cholecystokinin has consistently failed.
Mechanism
Cholecystokinin is produced from a single gene and processed into multiple bioactive forms sharing a common C-terminus. CCK-58, CCK-33, CCK-22 and CCK-8 are the principal circulating species. Biological activity resides in the C-terminal heptapeptide, and sulfation of the tyrosine seven residues from the C-terminus is essential for potency at the CCK1 receptor. Interestingly, the C-terminal five residues are identical to those of gastrin, which is why the two hormones cross-react at each other's receptors and why the receptor nomenclature was rationalised into CCK1 and CCK2.
CCK1 receptors (formerly CCK-A) are found on gallbladder smooth muscle, the sphincter of Oddi, the pyloric sphincter, pancreatic acinar cells in some species, and, most importantly for satiety, on vagal afferent terminals in the gut wall. Activation of vagal CCK1 receptors sends signals via the nodose ganglion to the nucleus tractus solitarius in the brainstem, which integrates with hypothalamic circuits to terminate the meal. This is a within-meal satiation signal: it determines when eating stops, not overall energy balance. CCK2 receptors (formerly CCK-B) are the gastrin receptors, found on gastric enterochromaffin-like cells and widely in the brain, where CCK acts as one of the most abundant neuropeptides. In humans, direct CCK2 stimulation by the unsulfated tetrapeptide CCK-4 is a reliable and potent panic-inducing agent, which is a striking illustration of how differently the two receptors behave.
What the research shows
The human satiety literature is genuinely consistent for acute effects. Kissileff and colleagues showed in 1981 that infusing the C-terminal octapeptide at 4 ng/kg/min reduced food intake by an average of 122 g in twelve lean men without evident adverse effects. Pi-Sunyer and colleagues replicated the finding in obese men in 1982, where six of eight participants ate significantly less and stopped eating sooner. Lieverse and colleagues showed in Gut in 1995 that CCK infusion to physiological plasma concentrations reduced food intake in both lean and obese women. A systematic review and meta-analysis by Warrilow and colleagues in the British Journal of Nutrition, published online in 2022 and in print in 2023, confirmed the aggregate acute effect across studies. Endogenous CCK is also implicated in the satiety benefit of bariatric surgery and of protein- and fat-rich meals.
The therapeutic story is the opposite. Repeated CCK administration produces rapid tachyphylaxis, and animals compensate by eating more frequent meals so that total daily intake is unchanged. The decisive human test came from Jordan and colleagues, who randomised overweight and obese patients to 24 weeks of the selective CCK1 agonist GI181771X or placebo alongside a hypocaloric diet: the drug did not reduce body weight and had no effect on waist circumference or other cardiometabolic risk markers, while gastrointestinal side effects were more frequent. The authors concluded that CCK1 by itself does not have a central role in long-term energy balance. Gallbladder and pancreatic imaging was performed because of concerns about pancreatitis and gallstones with sustained CCK1 stimulation; no organ damage emerged, but the concern shaped the programme. Cholecystokinin thus stands as a well-validated physiological satiation signal and a comprehensively failed drug target, a distinction worth holding on to, because CCK is still marketed to consumers on the strength of the physiology alone.
Evidence assessment
Mixed evidence
Acute reduction of food intake by intravenous cholecystokinin has been replicated in controlled human studies since 1981 and confirmed by a 2023 systematic review and meta-analysis in the British Journal of Nutrition, and sincalide holds regulator-approved US labelling as a diagnostic. But translation to therapy failed decisively: tachyphylaxis develops rapidly, and the 24-week randomised trial of the selective CCK1 agonist GI181771X produced no weight loss whatsoever. The satiety physiology is real; the therapeutic evidence is negative. All five citations were verified against PubMed.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
C-terminal octapeptide of cholecystokinin decreases food intake in man Preclinical only
Infusion at 4 ng/kg/min decreased food intake by an average of 122 g versus saline, with subjects stopping eating sooner. The first clear human demonstration supporting CCK as an endogenous postprandial satiety signal.
C-terminal octapeptide of cholecystokinin decreases food intake in obese men Preclinical only
Six of eight obese participants ate significantly less during CCK-8 infusion than saline, stopping eating sooner without changing eating rate. Established that CCK sensitivity is preserved in obesity.
Satiety effects of a physiological dose of cholecystokinin in humans Preclinical only
CCK infused to physiological plasma concentrations significantly reduced food intake in both obese and lean groups, showing the effect occurs at concentrations the body actually produces rather than only at pharmacological doses.
Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients Preclinical only
The drug did not reduce body weight and had no effect on waist circumference or other cardiometabolic risk markers. Gastrointestinal adverse events were more frequent than with placebo, without organ damage. The authors concluded CCK1 by itself does not have a central role in long-term energy balance. The definitive negative result for CCK1 agonism in obesity.
Role of cholecystokinin in satiation: a systematic review and meta-analysis Preclinical only
Confirmed a consistent acute reduction in food intake with exogenous CCK across studies, while highlighting the short duration of effect and absence of sustained energy balance change.
Safety
Cholecystokinin peptides given intravenously cause nausea, abdominal cramping and biliary colic-type pain from gallbladder contraction; these are dose-limiting and are the reason human infusion studies use narrow dose ranges. Sincalide's diagnostic labelling notes abdominal discomfort, nausea, dizziness and flushing, and it is used cautiously in patients with gallstones because forced gallbladder contraction can impact a stone. Sustained CCK1 receptor stimulation raises theoretical concerns about pancreatitis and gallstone formation, which is why the GI181771X trial included prospective imaging. Separately, the CCK2 agonist CCK-4 is one of the most reliable experimental panicogens in humans, producing intense panic attacks within seconds, a reminder that CCK peptides are not benign and that receptor selectivity matters enormously. Cholecystokinin sold as a research chemical for appetite control has no licensed status, no clinical evidence of sustained benefit, and a well-documented failure record at the drug-development stage.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | Sincalide is not licensed in the UK. Ceruletide (caerulein), a related decapeptide with cholecystokinin-like activity, was formerly marketed in some European countries but has largely been withdrawn. Cholecystokinin has no UK marketing authorisation for any therapeutic use, and CCK peptides sold to consumers are unlicensed research chemicals. |
| United States | Sincalide, the synthetic sulfated CCK octapeptide, is FDA-approved as a diagnostic agent for stimulating gallbladder contraction in hepatobiliary imaging, stimulating pancreatic secretion for duodenal aspiration testing, and accelerating small bowel barium transit. Cholecystokinin has no approved therapeutic indication. |
| WADA (sport) | Not listed on the WADA Prohibited List. There is no performance-enhancing rationale, and the demonstrated pharmacology (nausea and reduced food intake) runs against athletic performance. |
Questions
Acutely it reduces the size of a single meal. That is replicated and not in dispute, and a 2023 meta-analysis confirmed it. Sustained weight loss is a different matter, and here the answer is no. Tolerance develops within days, animals compensate by eating more meals, and a 24-week randomised trial of a selective CCK1 agonist in overweight and obese patients produced no weight loss at all.
Sincalide is the generic name for the synthetic sulfated CCK octapeptide. It is FDA-approved as a diagnostic agent: to contract the gallbladder during hepatobiliary imaging, to stimulate pancreatic secretion for duodenal aspiration testing, and to speed barium through the small bowel. It has no approved therapeutic use and is not licensed in the UK.
Sulfation of the tyrosine seven residues from the C-terminus increases potency at the CCK1 receptor by orders of magnitude. Without it, the peptide behaves much more like gastrin and acts preferentially at CCK2 receptors. This is why unsulfated CCK-4 causes panic attacks via CCK2 rather than satiety via CCK1.
Yes, they share an identical C-terminal five amino acids, which is why each can activate the other's receptor. The receptors were originally named CCK-A and CCK-B for this reason and were later renamed CCK1 and CCK2. The CCK2 receptor is, functionally, the gastrin receptor.